Vimarsana
Biggest News Aggregation in the World

Andreas Schaaf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Andreas Schaaf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Andreas Schaaf Today - Breaking & Trending Today

UAE's Albatha partners with Avis Budget to add Budget and Payless car rental brands to its portfolio - Vimarsana News

UAE's Albatha partners with Avis Budget to add Budget and Payless car rental brands to its portfolio

First Budget Rent a Car service counter will open at DXB Terminal 1 arrivals hall

AGMC speeds in with Chinese car brand Geely to make EVs affordable – but that is not all - Vimarsana News

AGMC speeds in with Chinese car brand Geely to make EVs affordable – but that is not all

Known for its BMW alliance, AMGC says it’s right time to go for ‘mainstream’ with Geely

EV startup Byton explores listing, report says - Vimarsana News

EV startup Byton explores listing, report says

EV startup Byton explores listing, report says Reuters Byton's first model will be the M-Byte SUV. SHANGHAI -- Chinese electric-vehicle maker Byton is in talks to go public through a merger with a special-purpose acquisition company (SPAC), people familiar with the matter told Reuters. Byton, whose key shareholders include China's state-owned automaker FAW Group and EV battery maker CATL, is in talks with potential SPAC companies and investors about the listing and plans to go public as early as this year, two sources, who declined to be named as the talks were private, said. Byton, which is ...

Strategic Funding to advance Drug Candidate - Vimarsana News

Strategic Funding to advance Drug Candidate

Strategic Funding to advance Drug Candidate Jan 14 2021 Read 170 Times Biologics manufacturer eleva GmbH has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. The company also announced the addition of Dr. Ralf Smit to its Executive Board. The Freiburg-based company developed its moss-based platform to produce biologics like antibodies, replacement enzymes, or fusion toxins. The funding from ZFHN...

Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member - Vimarsana News

Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member FREIBURG, Germany, Jan. 6, 2021 /PRNewswire/ — Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive Board. Eleva has been utilizing its unique moss-based platform to produce novel drugs. ZFHN, ...